

Market insights summary

# United States varicose vein treatment device market

## What's trending?

### 01. The rising prevalence of venous disease will drive sustained growth in varicose vein treatment volumes.

- Venous disease is widespread, affecting roughly one-third of adults, with progression to chronic venous insufficiency more common after age 50.
- Aging populations, obesity, and reduced mobility are expanding the treatable pool, while greater awareness of complications and minimally invasive options is driving earlier care-seeking.

### 02. There is a growing preference for minimally invasive endovenous ablation therapies and sclerotherapy agents.

- Thermal endovenous ablation remains the primary first-line therapy, but demand is shifting toward lower-pain, nontumescent nonthermal and sclerotherapy options.
- Adoption of nonthermal therapies and sclerotherapy agents is accelerating as emerging clinical evidence and greater reimbursement clarity—particularly improved payment predictability for Varithena and expanded coverage for cyanoacrylate adhesive—reduce access barriers.

Access more insights and data in the [report](#).  
[Speak to our team](#) to see how we can power your innovation.

## 2024 U.S. varicose vein treatment device market snapshot


**\$1.1B**

Market revenue


**9.0%**

CAGR ('19-'34)

### U.S. varicose vein treatment device market



### 2024 U.S. competitive landscape



### Boston Scientific

- Boston Scientific strengthened its leadership in the varicose vein treatment device market in 2024, surpassing Medtronic, driven by strong uptake of Varithena and its unique position as the only provider of a microfoam sclerosant.
- With Varithena benefiting from demonstrated clinical advantages and favorable reimbursements, Boston Scientific is well positioned to sustain its market leadership.

### Medtronic

- Although Medtronic previously held the leading position in the varicose vein treatment device market through its early entry with VenaSeal—the first nonthermal cyanoacrylate adhesive device—and its strong presence in the thermal endovenous ablation segment with ClosureFast, the company has fallen to second place, behind Boston Scientific in the overall market, while continuing to lead the endovenous ablation segment.